Innovative Clinical Research Institute

Summary

Innovative Clinical Research Institute is a medical facility located in Whittier, California. This center is recognized for care of Lung Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Pancreatic Cancer, Cancer and other specialties. Innovative Clinical Research Institute is involved with conducting 123 clinical trials across 119 conditions. There are 9 research doctors associated with this hospital, such as Omkar S Marathe, Richy Agajanian, MD, Paul La Porte, and Amitabha Mazumder.

Top PIs

Clinical Trials running at Innovative Clinical Research Institute

Cancer

Lung Cancer

Chronic Lymphocytic Leukemia

Follicular Lymphoma

B-Cell Leukemia

Lymphoma

Pancreatic Cancer

Breast Cancer

Relapse

Multiple Myeloma

Continued Darolutamide Treatment

for Cancer

This trial continues darolutamide treatment for patients who were part of a previous study and are believed to benefit from it. Darolutamide helps by blocking hormones that can make cancer cells grow. Patients will keep taking the same dosage and visit their doctors regularly. Darolutamide has been shown to slow cancer spread and improve survival in patients with nonmetastatic castration-resistant prostate cancer.

Recruiting

2 awards

Phase 3

4 criteria

Pralatrexate

for Cancer

This purpose of this study is to help to evaluate the pharmacokinetic (PK) profile of pralatrexate when administered to patients with various degrees of hepatic impairment and to evaluate the safety and establish the dosing recommendations for pralatrexate administered once weekly for 6 weeks of every 7-week treatment cycle in patients with hepatic impairment. Pharmacokinetics (or PK) is the study of how your body absorbs, breaks down, and removes a study drug.

Recruiting

1 award

Phase 1

5 criteria

DB-1303

for Solid Cancers

This trial is testing a new drug called DB-1303 to see if it is safe for patients with advanced solid tumors that express HER2. The study will begin with lower doses and increase them over time to find the highest dose that patients can handle. This helps determine the best dose for future studies.

Recruiting

1 award

Phase 1 & 2

2 criteria